Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. Its product pipeline includes MOB-015, which is a treatment for nail fungus. The company was founded by Peter Gunnar Maurits Wolpert and Marie Moberg in March 2006 and is headquartered in Bromma, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company